EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2019 to Jul 2024
EDAP TMS S.A. Confirms Strong 2004 Revenue Performance
- HIFU with ABLATHERM(R) Business Taking Off -
LYON, France, Jan. 14 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP),
ahead of the release of its 2004 annual results scheduled for mid-March 2005,
today confirms strong sales revenue growth and steady cash position for the
full year of 2004.
The Company's expectations for the full year of 2004 are based on an over 20%
increase in sales revenue, strengthened gross margins and significant expense
reductions versus year 2003, aiming at positive operating income in both
divisions.
This progression over year 2004 includes a dramatic approximate 140% increase
in Ablatherm(R) (devices and mobile business) sales which confirms the growing
interest for HIFU for the treatment of localized prostate cancer. EDAP clinical
and technological leadership in HIFU, with more that 6,000 treatments performed
so far, strengthens its credibility and therefore reinforces this high growth
business trend.
The Lithotripsy activity today definitely provides momentum for the overall
Group business as it ensures a regular and steady business with predictable
high margins and significant recurring service revenues. The Lithotripsy
business was maintained over year 2004 on a very mature market, despite the
strengthening of the Euro against the Japanese Yen and the US Dollar.
Group cash position remains strong at over Euros 9.3 million (USD 12.7 million)
as of end of December 2004. This cash level was maintained throughout 2004.
Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We are
pleased with our 2004 preliminary figures. The significant progression recorded
on our Ablatherm(R) sales together with the dramatic increase in the number of
patients treated with HIFU confirm the high growth opportunity of the HIFU with
Ablatherm(R) business. EDAP's current successful experience in developing and
controlling its lithotripsy sales and service business will pave the way in
setting-up the HIFU with Ablatherm(R) business model. We look forward to
reporting further on our 2004 results later in March."
EDAP TMS S.A. is the global leader in the development, production, marketing
and distribution of a portfolio of minimally invasive medical devices primarily
for the treatment of urological diseases. The Company currently develops and
markets Ablatherm(R) for the minimally invasive treatment of localized prostate
cancer, using High Intensity Focused Ultrasound (HIFU), through its HIFU
Division; it is also developing this technology for the treatment of certain
other types of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL), via its Urology Devices and Services (UDS) Division. For
more information on the Company, contact our Investor Relations Dept by phone
at +33 (0)4 78 26 40 46 or please see the Company's web site at:
http://www.edap-tms.com/.
This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.
Contact: Hugues de Bantel, Philippe Chauveau or Blandine Confort
+33 4 78 26 40 46
DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel, Philippe Chauveau or Blandine Confort, all of
EDAP TMS S.A., +33-4-78-26-40-46
Web site: http://www.edap-tms.com/